We included 331 cognitively normal (CN) individuals, 196 patients with mild cognitive impairment (MCI) and 65 patients with clinically diagnosed dementia all with available baseline amyloid-PET (i.e., [18F]florbetaben/[18F]florbetapir, n = 197/395), [18F]flortaucipir tau-PET and CSF-based αSyn data based on a pre-established SAA (Amprion, San Diego, CA) to determine the αSyn status [30]. The gene discussed is MAPT; the disease is Cognitive impairment.